Report

Transmission and Pathogenesis of Swine-Origin 2009 A(H1N1) Influenza Viruses in Ferrets and Mice

See allHide authors and affiliations

Science  24 Jul 2009:
Vol. 325, Issue 5939, pp. 484-487
DOI: 10.1126/science.1177238

“Swine Flu” Pathology

The clinical spectrum of disease caused by the swine-origin 2009 A(H1N1) influenza virus and its transmissibility are not completely understood. Munster et al. (p. 481; published online 2 July) and Maines et al. (p. 484; published online 2 July) used ferrets, an established model for human influenza, to evaluate the pathogenesis and transmissibility of a selection of 2009 A(H1N1) virus isolates compared with representative seasonal H1N1 viruses. The results help explain the atypical symptoms seen so far, including the gastrointestinal distress and vomiting observed in many patients. Although results were variable, it seems that the 2009 A(H1N1) virus may be less efficiently transmitted by respiratory droplets in comparison to the highly transmissible seasonal H1N1 virus, suggesting that additional virus adaptation in mammals may be required before we see phenotypes observed in earlier pandemics.

Abstract

Recent reports of mild to severe influenza-like illness in humans caused by a novel swine-origin 2009 A(H1N1) influenza virus underscore the need to better understand the pathogenesis and transmission of these viruses in mammals. In this study, selected 2009 A(H1N1) influenza isolates were assessed for their ability to cause disease in mice and ferrets and compared with a contemporary seasonal H1N1 virus for their ability to transmit to naïve ferrets through respiratory droplets. In contrast to seasonal influenza H1N1 virus, 2009 A(H1N1) influenza viruses caused increased morbidity, replicated to higher titers in lung tissue, and were recovered from the intestinal tract of intranasally inoculated ferrets. The 2009 A(H1N1) influenza viruses exhibited less efficient respiratory droplet transmission in ferrets in comparison with the highly transmissible phenotype of a seasonal H1N1 virus. Transmission of the 2009 A(H1N1) influenza viruses was further corroborated by characterizing the binding specificity of the viral hemagglutinin to the sialylated glycan receptors (in the human host) by use of dose-dependent direct receptor-binding and human lung tissue–binding assays.

On 11 June 2009, the World Health Organization (WHO) raised the global pandemic alert level to phase 6, the pandemic phase, in response to the emergence and global spread of a novel influenza A(H1N1) virus that contains a previously unseen combination of genes of swine origin (1). Leading up to this event were reports of increased numbers of patients with influenza-like illness and associated hospitalizations and deaths in several areas of Mexico during March and April (2). On 15 and 17 April 2009, two unrelated cases of febrile respiratory illness in children who resided in adjacent counties in southern California were confirmed to be caused by infection with a swine-origin A(H1N1) influenza virus (3, 4), hereafter referred to as 2009 A(H1N1) influenza viruses. In the period of March to 21 June 2009, there have been over 44,000 laboratory-confirmed human cases of 2009 A(H1N1) influenza virus infections reported in 85 countries on six continents (5). Although most confirmed cases have occurred among individuals with uncomplicated, febrile, upper respiratory tract illnesses with symptoms similar to those of seasonal influenza, there have been over 180 deaths, and approximately 40% of infected individuals have experienced symptoms that include gastrointestinal distress and vomiting, which is higher than that reported for seasonal influenza (6). The current case fatality rate of this global outbreak is uncertain, as is the total number of persons infected with the 2009 A(H1N1) influenza virus (7).

The factors that lead to the generation of pandemic viruses are complex and poorly understood; however, the ability of a novel influenza virus to cause substantial illness and transmit through the air are critical properties of pandemic influenza strains (810). Thus, knowing the inherent virulence and transmissibility of the 2009 A(H1N1) influenza viruses, relative to seasonal influenza viruses, is important for executing appropriate public health responses.

We have therefore characterized the pathogenesis and transmissibility of three 2009 A(H1N1) influenza viruses (isolated from nasopharyngeal swabs) in the ferret (Mustela putorius furo) model, which appears to recapitulate not only human disease severity but also efficient transmission of seasonal (H1N1 and H3N2) influenza viruses and the poor transmission of avian (H5 and H7) influenza viruses (1114). A/California/04/2009 (CA/04) virus was isolated from a pediatric patient with uncomplicated, upper respiratory tract illness; A/Mexico/4482/2009 (MX/4482) virus was isolated from a 29-year-old female patient with severe respiratory disease; and Texas/15/2009 (TX/15) virus was isolated from a pediatric patient with fatal respiratory illness. The three 2009 A(H1N1) influenza viruses were compared with a representative seasonal H1N1 virus, A/Brisbane/59/2007 (Brisbane/07; H1N1) (14). To date, 2009 A(H1N1) influenza viruses exhibit high genome-sequence identity (99.9%) and lack previously identified molecular markers of influenza A virus virulence or transmissibility (1). Alignments of the deduced amino acid sequences between the three viruses that we studied revealed a few differences. These were observed in the hemagglutinin (HA), neuraminidase (NA), polymerase (PA), nucleoprotein (NP), and nonstructural proteins NS1 and NS2 (table S1). Viruses were propagated in Madin-Darby canine kidney (MDCK) cells or embryonated hens’ eggs (15).

For respiratory droplet–transmission experiments, three ferrets were inoculated intranasally with 106 plaque-forming units (PFU) of virus (15). Approximately 24 hours later, inoculated-contact animal pairs were established by placing a naïve ferret in each of three adjacent cages with perforated side walls, allowing the exchange of respiratory droplets without direct or indirect contact (11). Direct-contact transmission experiments were performed similarly, except that naïve ferrets were placed in the same cage as each of the inoculated ferrets, where they shared a common food and water source. Inoculated and contact animals were monitored for clinical signs over a 14-day period. Transmission was assessed by means of titration of infectious virus in nasal washes and detection of virus-specific antibodies in convalescent sera (11). Three additional inoculated ferrets from each virus-infected group were euthanized on day 3 after inoculation for assessment of infectious virus in tissues (15).

Ferrets inoculated with CA/04 virus showed no overt clinical signs but displayed mild signs of inactivity [relative inactivity index (RII) = 1.0]. TX/15 or MX/4482 virus infection resulted in more pronounced clinical features, including a slight increase in RII (1.2). Significantly greater weight loss was observed in all ferrets with the 2009 A(H1N1) influenza viruses than in those with the seasonal influenza virus, Brisbane/07 (P < 0.05) (Table 1). One ferret infected by means of direct-contact transmission from a TX/15-inoculated ferret was euthanized at 10 days after inoculation because of excessive weight loss, and three of six MX/4482-inoculated ferrets were euthanized before the end of the experimental period because of severe lethargy or excessive weight loss (Table 1). Ferrets inoculated with any of the 2009 A(H1N1) influenza virus isolates shed high peak mean titers of infectious virus in nasal washes as early as day 1 after inoculation (107.1–7.7 PFU/ml) (figs. S1 and S2) that were sustained at titers of ≥104.4 PFU/ml for 5 days after inoculation. The 2009 A(H1N1) influenza virus–shedding showed kinetics similar to Brisbane/07 virus, which was also sustained for 5 days in ferrets at titers of ≥104.7 PFU/ml. In contrast to Brisbane/07, the CA/04, TX/15, and MX/4482 viruses were detected in the lower respiratory tract at high titers (105.8–6.0 PFU/g lung tissue) and the intestinal tract. For the latter, viral titers were detected in rectal swabs or tissue samples collected throughout the intestinal tract (Table 1 and fig. S3). There was no evidence of viremia or infectious virus in the brain, kidney, liver, and spleen tissues with any of the viruses tested (fig. S3).

Table 1

Replication and transmission of 2009 A(H1N1) influenza viruses and a seasonal H1N1 virus in ferrets.

View this table:

Consistent with the experimental transmission data obtained with contemporary human H1N1 and H3N2 viruses (11, 14, 16), the seasonal influenza H1N1 (Brisbane/07) virus efficiently transmitted via direct contact and respiratory droplets to all of the contact ferrets that shed virus as early as day 1 after contact (figs. S1 and S2). Direct contact transmission was observed between all animal pairs for CA/04, TX/15, and MX/4482 viruses; infectious virus was recovered from nasal washes, and seroconversion was detected in all contact animals (Table 1 and fig. S1). However, the 2009 A(H1N1) influenza viruses did not spread through respiratory droplet to every contact ferret, and transmission was delayed by 5 or more days after exposure in two of six infected ferret pairs (fig. S2). Respiratory droplet transmission of 2009 A(H1N1) influenza viruses was significantly reduced as compared with respiratory droplet transmission of the seasonal influenza virus (P ≤ 0.01) (Table 1). Sneezing was frequently observed in Brisbane/07–inoculated ferrets but was rarely observed in the CA/04–, TX/15–, or MX/4482–inoculated ferrets during the study period, which is similar to the infrequent sneezing observed in ferrets infected with avian influenza viruses (11). Collectively, these findings demonstrate that 2009 A(H1N1) influenza viruses elicited elevated respiratory disease relative to seasonal H1N1 viruses in ferrets, yet despite efficient direct-contact transmission, the viruses exhibited less efficient respiratory droplet transmission as compared with that of contemporary seasonal human influenza viruses (11, 14).

The binding of influenza viruses to their target cells is mediated by viral HA, and binding preference to specific sialylated glycan receptors is a critical determinant of H1N1 virus transmission efficiency in ferrets (14, 17, 18). We examined the glycan-binding properties of the 2009 A(H1N1) HA by means of dose-dependent direct receptor-binding (18) and human lung tissue–binding assays using recombinantly expressed soluble CA/04 HA (19). In the direct glycan receptor–binding assay, CA/04 HA exhibited a dose-dependent binding to only a single α2-6 glycan (6′SLN-LN) and only minimal binding to α2-3 glycans (Fig. 1). Although the binding pattern of CA/04 HA is similar to that of HA from the 1918 pandemic influenza A virus [A/South Carolina/1/1918 (SC18)], the binding affinity of CA/04 HA is considerably lower than that of SC18 HA (figs. S4 and S5). Examining the tissue binding of CA/04 HA indicates that it binds uniformly to the apical surface of the human tracheal (representative upper respiratory) tissue sections (Fig. 2). This binding pattern correlates with the predominant distribution of α2-6 sialylated glycans on the apical surface of the tracheal tissue (19) and the α2-6 binding of CA/04 HA in the direct binding assay. Although CA/04 shows some binding to alveolus, it is not as extensive as the tracheal binding that is consistent with the minimal α2-3 binding observed in the direct binding assay.

Fig. 1

Dose-dependent direct receptor-binding of CA/04 HA. A streptavidin plate array consisting of representative biotinylated α2-3– and α2-6–sialylated glycans were used for the assay. The biotinylated glycans include 3′SLN, 6’SLN, 3′SLN-LN, 6′SLN-LN, and 3′SLN-LN-LN. LN corresponds to lactosamine (Galβ1-4GlcNAc), and 3′SLN and 6’SLN correspond to Neu5Acα2-3 and Neu5Acα2-6 linked to LN, respectively. The assay was carried out as previously described (18) for an entire range of HA concentration from 0.01 to 40 μg/ml by precomplexing HA:primary antibody:secondary antibody in the ratio 4:2:1 in order to enhance the multivalent presentation of HA. The binding signals for HA concentrations below 1 μg/ml were at background level, and so their concentrations are not shown on the x axis. The y axis shows the normalized binding signal as a percentage of the maximum value.

Fig. 2

Human tissue binding of CA/04 HA. Shown to the left is the binding of CA/04 HA at 20 μg/ml concentration to the apical surface (white arrow) of human tracheal tissue sections (green; propidium iodide staining is in red). The apical surface of tracheal tissue is known to predominantly express α2-6–sialylated glycans (19). The binding of the recombinantly expressed HA to the human tissues was carried out as previously described (19) by precomplexing HA:primary antibody:secondary antibody in the ratio 4:2:1 in order to enhance multivalent presentation of HA. Shown to the right is the minimal binding of HA at 20 μg/ml concentration to the alveolar tissue section. The sialic acid–specific binding of HA to the tracheal tissue section was confirmed by means of blocking HA binding to the tissue section pretreated with 0.2 U of sialidase (recombinant from Arthrobacter ureafaciens).

The receptor-binding site (RBS) of the 2009 A (H1N1) HAs (20), used in this study, were compared with those from SC18 and the recent seasonal influenza H1N1 viruses (Table 2). The similarity in the binding pattern between CA/04 HA and SC18 HA could potentially arise from the majority of the “similar or analogous” RBS residues between these HAs, including Asp190 and Asp225, which are “hallmark” amino acids of human-adapted H1N1 HAs that make optimal contacts with the α2-6 glycans. The main differences in RBS between SC18 and CA/04 HA are at positions 145, 186, 189, 219, and 227. The CA/04 HA has a Lys145 that provides an additional anchoring contact for the sialic acid (20). The residues at 186, 187, and 189 are positioned to form an interaction network with Asp190 (18, 20). In the case of SC18 HA, this network involves oxygen atoms of Thr187, Thr189, and Asp190 (18). In a similar fashion, in the case of CA/04 HA this network could potentially be formed by the oxygen atoms of Ser186, Thr187, and Asp190. The residues 219 and 227 in turn influence the orientation of residue 186. Comparison of residues 219 and 227 (Table 2) reveals that either both amino acids are hydrophobic, such as Ala219 and Ala227 (as observed in SC18 HA), or they are charged residues, such as Lys219 and Glu227 (as observed in the seasonal influenza HAs). The 2009 A(H1N1) HAs have a combination of Ile219 and Glu227 that results in a set of interactions that is neither fully hydrophobic nor fully charged. This combination could destabilize the hydrophobic or ionic network of residues at 186, 219, and 227, disrupting optimal contacts with the α2-6 sialylated glycans (Fig. 3). Analysis of the RBS of the 2009 A(H1N1) HA offers an explanation for the lower α2-6–binding affinity of CA/04 HA as compared with that of SC18 HA, despite the similar binding pattern (fig. S4). Taken together, the differences in the glycan-binding property of the 2009 A(H1N1) HA when compared with that of SC18 and the recent seasonal influenza HAs correlate with the observed differences in the respiratory droplet transmission in ferrets.

Table 2

Glycan-binding residues of H1N1 HAs. The residues are organized into network-forming clusters. The sugar unit (numbered as shown in Fig. 3), which makes contact with the clusters, is shown in the last row. The amino acids specific to 2009 H1N1 HAs are highlighted in red. SolIS_3_06, A/Solomon Islands/3/06; Bris_59_07, A/Brisbane/59/07; NewCal_20_99, A/New Caledonia/20/99; TX_36_91, A/Texas/36/91.

View this table:
Fig. 3

Structural model of CA/04 HA bound to α2-6 oligosaccharide. The contacts of CA/04 HA with an α2-6 oligosaccharide (Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4Glc) were analyzed through the construction of a structural model as previously described (20). Shown in the figure is the illustrated representation of the glycan-binding site of CA/04 HA; the side chains of the key amino acids are shown in stick representation (carbon, gray; oxygen, red; nitrogen, blue). The α2-6 oligosaccharide is shown as a stick representation (carbon, green; oxygen, red; nitrogen, blue) and labeled blue starting from the nonreducing end Neu5Ac-1 to the reducing end Glc-5. The potential destabilization of the interaction network due to the Ile219/Glu227 combination is highlighted in the red dotted circle.

To evaluate the pathogenicity of the novel H1N1 viruses in another mammalian species, we inoculated BALB/c mice intranasally with three 2009 A(H1N1) influenza virus isolates and then determined virus replication, morbidity (as measured by weight loss), 50% mouse infectious dose (MID50), and 50% lethal dose (LD50) titers. In addition to CA/04 and TX/15, A/Mexico/4108/2009 (Mx/4108; H1N1) virus, obtained from a hospitalized case of nonfatal infection, was included in the mouse pathotyping experiments. The 2009 A(H1N1) influenza viruses isolates did not kill mice [LD50 >106 PFU or 50% egg infection dose (EID50)], which displayed only transient weight reduction (Table 3); however, all three 2009 A(H1N1) influenza viruses replicated efficiently in mouse lungs without prior host adaptation (Table 3). Typically, human influenza A strains of the H1N1 subtype replicate efficiently in mice only after they are adapted to growth in these animals (21). The MID50 titers, determined through the detection of virus in the lungs of mice 3 days after inoculation, were markedly low (MID50 = 100.5–1.5 PFU or EID50), indicating high infectivity in this model. We next determined whether 2009 A(H1N1) influenza viruses replicated systemically in the mouse after intranasal infection, a characteristic of virulent avian influenza (H5N1) viruses isolated from humans but not of 1918 (H1N1) virus (17, 22). All mice infected with CA/04, TX/15, or MX/4108 viruses had undetectable levels (<10 PFU/ml) of virus in whole spleen, thymus, brain, and intestinal tissues, indicating that the 2009 A(H1N1) influenza viruses did not spread to extrapulmonary organs in the mouse.

Table 3

Pathogenicity of 2009 A(H1N1) influenza viruses in BALB/c mice.

View this table:

The full clinical spectrum of disease caused by 2009 A(H1N1) influenza viruses and its transmissibility are not completely understood. The present study shows that overall morbidity and lung viral titers were higher in ferrets infected with 2009 A(H1N1) influenza virus isolates as compared with those infected with the seasonal H1N1 virus. Moreover, the detection of 2009 A(H1N1) influenza viruses in the intestinal tissue of ferrets is consistent with gastrointestinal involvement among some human 2009 A(H1N1) cases (6). Although the 2009 A(H1N1) influenza viruses demonstrated similar replication kinetics as the seasonal H1N1 virus in the upper respiratory tract of inoculated ferrets, the 2009 A(H1N1) influenza viruses did not spread to all naïve ferrets by means of respiratory droplets. This lack of efficient respiratory droplet transmission suggests that additional virus adaptation in mammals may be required to reach the high-transmissible phenotypes observed with seasonal H1N1 or the 1918 pandemic virus (14, 17).

It was demonstrated previously (17) that the efficiency of respiratory droplet transmission in ferrets correlates with the α2-6–binding affinity of the viral HA. In fact, a single amino acid mutation in HA of the efficiently transmitting SC18 virus led to a virus (NY18) that transmitted inefficiently (fig. S5). The α2-6–binding affinity of NY18 HA was substantially lower than that of SC18 HA (fig. S5). In a similar fashion, the substantially lower α2-6–binding affinity of CA/04 HA than that of SC18 HA correlates with the less efficient 2009 A(H1N1) influenza virus respiratory droplet transmission (fig. S5).

Adaptation of the polymerase basic protein 2 (PB2) is also critical for efficient aerosolized respiratory transmission of an H1N1 influenza virus (14, 17, 23). A single amino acid substitution from glutamic acid to lysine at amino acid position 627 supports efficient influenza virus replication at the lower temperature (33°C) found in the mammalian airway and contributes to efficient transmission in mammals (14, 23). All three of the 20th-century influenza pandemics were caused by viruses containing human adapted PB2 genes, and in general lysine is present at position 627 among the human influenza viruses, whereas a glutamic acid is found in this position among the avian influenza isolates that fail to transmit efficiently among ferrets (14). In contrast to the Brisbane/07 virus and other seasonal H1N1 viruses, all 2009 A(H1N1) influenza viruses to date with an avian influenza lineage PB2 gene possess a glutamic acid at residue 627 (1). The phenotype of PB2 is determined by the amino acid at position 627, which can arise by mutant selection or reassortment, and along with adaptive changes in the RBS should be closely monitored as markers for enhanced virus transmission.

Supporting Online Material

www.sciencemag.org/cgi/content/full/1177238/DC1

Materials and Methods

Figs. S1 to S5

Table S1

References

References and Notes

  1. Materials and methods are available as supporting material on Science Online.
  2. We thank P. Blair (Naval Health Research Center, San Diego), G. J. Demmler (Texas Children’s Hospital, Houston), C. Alpuche-Aranda [Instituto de Diagnóstico y Referencia Epidemiológicos, Mexico], and the WHO Collaborating Centre for Reference and Research on Influenza (Melbourne) for facilitating access to viruses. We also thank X. Lu and A. Balish for preparation of viruses and V. Veguilla for statistical analysis. R.S. acknowledges the consortium for functional glycomics for providing glycan standards and support from the Singapore-MIT Alliance for Research and Technology and the National Institute of General Medical Sciences of the NIH (GM 57073 andU54 GM62116). Confocal microscopy of the human lung tissue sections was performed at the W. M. Keck Foundation Biological Imaging Facility at the Whitehead Institute. The findings and conclusions in this report are those of the authors and do not necessarily reflect the views of the funding agency.
View Abstract

Navigate This Article